期刊文献+

威猛(Vm-26)对Hela细胞染色体形成的影响 被引量:3

THE EFFECTS OF Vm-26 ON THE FORMATION OF HELACELL CHROMOSOME
下载PDF
导出
摘要 抗癌药物Vm-26是一种拓朴异构酶(TopoisomeraseⅡ,TopoⅡ)及组蛋白Hl激酶的抑制剂。本文就其对Hela细胞染色体形成的影响进行了观察。不同浓度的Vm-26加入Hela细胞培养液后48小时,进行染色体制备,光镜观察。当Vm-26的培养浓度在0.5-1.0μg/ml时,染色体的形成被阻断于分裂前期。当药物培养浓度于0.25μg/ml时,可见有相当数量的细胞处于分裂前期,其胞核内具有不规则的染色质凝缩。另外,尚可见极少的分裂中期染色体集簇形成,但大都伴有染色体的结构异常。结果提示:Vm-26可以通过抑制Hela细胞染色体的形成,而影响细胞正常的分裂、繁殖。 The antineoplastic agent,teniposide(Vm-26)is a inhibitor of the topoisomeraseⅡ(TopoⅡ).It can block the histone Hl phoshorylation. Its effects on the formation of Helacell chromosome was studied. The cell were cultured in diHerent concentration of Vm-26for 48 hours.Through preparation and observation of the chromosome with the conventionalrnethod,we noted that the chromosomal formation was blocked at G2 phase when the Vm- 26 was in a cuItured concentration of 0.5-1.0μg/ml.Mitotic cells were found to be pres- ence in 0.25μg/ml Vm- 26,but most of them failed to condense into the normal metaphasespreads,which always showed an irregular chromatin substance in the nuclei,or structure al- tered chromosomes.The results indicated that Vm- 26 can blocked Hela cell division by in-hibiting its chromosome formation,mainly acting on the late step of chromosome condensa- tion,while the chromatin fibers condense to form mitotic chromosome.
出处 《癌变.畸变.突变》 CAS CSCD 1996年第3期161-164,共4页 Carcinogenesis,Teratogenesis & Mutagenesis
关键词 抗癌药 威猛 染色体形成 染色体凝缩 细胞分裂 chromosome formation chromosome condensation Vm- 26 abnormal chromo-somes cell division
  • 相关文献

同被引文献12

  • 1Sinha BK. Topoisomerase inhibitors-a review of their therapeutic potential in cancer[J]. Drugs, 1995,49(1): 11-19.
  • 2Fortune JM, Osheroff N. Merbarone inhibits the catalytic activity othuman topoisomerase Ⅱ α by blocking DNA cleavage[J]. J Biol Chem, 1998, 273(28) : 17 643 - 17 650.
  • 3Nagata T, Higashigawa M, Shimono Y, et al. Aclarubicine inhibits etoposide induced apoptosis through inhibition of RNA synthesis in P388 mutine leukemia cens[J]. J Exp Clin Cancer Res,1998, 17(4) : 435 - 443.
  • 4Grue P, Grabert A, Sehested M, et al. Essential mitotic function of DNA topoisomerase Ⅱ α are not adopted by topoisomerase Ⅱ β in human H69 cells[J]. J Biol Chem, 1998, 273(50) : 33 660 -33 666.
  • 5Warburton PE, Eamshaw WC. Untangling the role of DNA topoisomerase Ⅱ in mitotic chromosome structure and function[J]. Bio Essays, 1995, 19(2) : 97 - 99.
  • 6Charron M, Hancock R. DNA topoisomerase Ⅱ is required for formation of mitotic chromosomes in Chinese hamster ovary cells:Studies using the inhibitor 4'-Demethylepipodophyllotoxin 9-(4,60-Thenylidem-β-d-glucopyranoside)Biochem,1990,29(41): 531- 9 537.
  • 7Chen M, Beck W. Differences in inhibition of chromosome separation and G2 arrest by DNA topoisomerase Ⅱ inhibitors Merbarone and VM-26[J]. Cancer Res, 1995, 55(7) : 1 509- 1 516.
  • 8Gorbsky GJ. Cell cycle progression and chromosome segregation in mammalian cell cultured in the presence of the tpoisomerase Ⅱ inhibitors ICRF-187[( + ) - 1, 2- his(3, 5-dioxopiperazinyl-l-yl)propane; ADR-529] and ICRF-159 (Razoxane)[J]. Career Res,1994, 54(4) : 1 042 - 1 048.
  • 9Slee EA, Adrain C, Martin SJ. Executioner caspase-3, 6, 7 perform distinct, non-redundant roles during the demolition phase of apoptesis[J]. J Biol Chem, 2001, 276(10): 7 320-7 326.
  • 10Benjamin CW, Hiebsch RR, Jones DA. Caspases activation in MCF7 cells responding to etoposide treatment[J]. Mol Pharmacol, 1998, 53(3) : 446- 450.

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部